Q-omics provides the consensus-scored CCNG1 profile across patient tissues and cancer cell-line models. CCNG1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCNG1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CCNG1 RNA expression shows 19,509 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CCNG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNG1 survival associations across molecular data types. CCNG1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNG1 RNA expression–survival associations across cancer types. High CCNG1 expression shows unfavorable associations in ESCA, SCLC, LUSC and LGG, but favorable associations in KIRC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCNG1 RNA expression.
This table summarizes CCNG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCNG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNG1 shows lower tumor expression in HNSC, LUSC and BRCA and higher tumor expression in KIRC, LIHC and THCA. The KIRC box plot shows higher CCNG1 RNA expression in tumor versus normal tissue (log2 FC = +0.485, t-test p < 0.001).
This table shows molecular features associated with CCNG1 in patient tissues and cancer cell lines. In patient samples, CCNG1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCNG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
